PDS Biotechnology Co. (NASDAQ:PDSB) Forecasted to Post FY2028 Earnings of $0.33 Per Share

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 earnings estimates for shares of PDS Biotechnology in a research report issued on Wednesday, March 27th. HC Wainwright analyst J. Pantginis forecasts that the company will earn $0.33 per share for the year. HC Wainwright currently has a "Buy" rating and a $21.00 price objective on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.43) per share.

Several other analysts have also issued reports on PDSB. Cantor Fitzgerald reissued an "overweight" rating on shares of PDS Biotechnology in a report on Friday, January 12th. B. Riley reiterated a "buy" rating and issued a $11.00 price target (down previously from $14.00) on shares of PDS Biotechnology in a research note on Thursday. Finally, StockNews.com downgraded PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, March 16th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.33.

PDS Biotechnology Price Performance

Shares of PDSB stock traded up $0.11 during trading on Thursday, hitting $3.96. The company had a trading volume of 2,283,905 shares, compared to its average volume of 883,386. The firm has a market capitalization of $123.20 million, a P/E ratio of -2.32 and a beta of 1.72. PDS Biotechnology has a one year low of $3.61 and a one year high of $10.27. The company has a debt-to-equity ratio of 0.96, a quick ratio of 6.21 and a current ratio of 6.21. The stock's 50-day moving average price is $5.26 and its 200 day moving average price is $5.10.

Institutional Trading of PDS Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in shares of PDS Biotechnology by 276.6% in the second quarter. BlackRock Inc. now owns 1,732,918 shares of the company's stock valued at $8,717,000 after buying an additional 1,272,801 shares during the period. Vanguard Group Inc. increased its position in PDS Biotechnology by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,148,078 shares of the company's stock valued at $3,410,000 after purchasing an additional 54,193 shares during the period. Renaissance Technologies LLC raised its holdings in PDS Biotechnology by 49.5% during the 1st quarter. Renaissance Technologies LLC now owns 665,037 shares of the company's stock worth $4,117,000 after purchasing an additional 220,300 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of PDS Biotechnology by 18.6% in the 1st quarter. Two Sigma Investments LP now owns 589,050 shares of the company's stock valued at $3,623,000 after purchasing an additional 92,581 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in PDS Biotechnology by 4.5% during the first quarter. Two Sigma Advisers LP now owns 584,400 shares of the company's stock worth $3,594,000 after buying an additional 25,200 shares during the last quarter. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.